Iluvien

Type: Product
Name: Iluvien
First reported 19 hours ago - Updated 19 hours ago - 1 reports

Your September Biotech Back-to-School Calendar

08/26/14 - 09:50 AM EDTBOSTON ( TheStreet ) -- If you're like me, a dad with school-age kids, September is a real page turner in the calendar. Everyone gets a fresh start on January 1, but Labor Day serves the same purpose. The lazy days of summer are ... [Published TheStreet.com - 19 hours ago]
First reported Aug 22 2014 - Updated Aug 23 2014 - 1 reports

Alimera Sciences reports net income for Q2

Alimera Sciences, Inc., a biopharmaceutical company, has reported that net income applicable to common stockholders for the second quarter ended June 30, 2014 was $1.12 million, or $0.16 per diluted share, compared to a net loss applicable to common stockholders ... [Published Individual.com - Aug 22 2014]
First reported Aug 21 2014 - Updated Aug 21 2014 - 1 reports

3 smart-money growth stocks to boost your returns

With the  S&P/ASX 200 Index  (INDEXASX: XJO) near its highest point in over six years investors should ensure that they’re invested in high quality companies with bright futures. As Warren Buffett famously said: “Only when the tide goes out do you discover ... [Published Motley Fool - Aug 21 2014]
First reported Aug 16 2014 - Updated Aug 16 2014 - 1 reports

ALIMERA SCIENCES : Reports 2Q Financial Results

Alimera Sciences reported financial results for the second quarter ended June 30 ."We achieved an important milestone during the second quarter of 2014 as more commercial patients have now been injected with Iluvien than were treated in our clinical trials. ... [Published 4 Traders - Aug 16 2014]
First reported Aug 11 2014 - Updated Aug 12 2014 - 2 reports

Alimera Sciences Issues 2Q Financial Results

Alimera Sciences reported financial results for the second quarter ended June 30. "We achieved an important milestone during the second quarter of 2014 as more commercial patients have now been injected with Iluvien than were treated in our clinical trials. ... [Published Individual.com - Aug 12 2014]
First reported Aug 10 2014 - Updated Aug 10 2014 - 1 reports

Alimera Sciences' (ALIM) CEO Charles Myers on Q2 2014 Results - Earnings Call Transcript

OperatorGood day, ladies and gentlemen, and welcome to the Alimera Sciences Second Quarter 2014 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would like to introduce your host for today's conference, ... [Published Seeking Alpha - Aug 10 2014]
First reported Aug 07 2014 - Updated Aug 08 2014 - 3 reports

Alimera reports net revenue of $2.2 million in second quarter

Alimera Sciences reported second quarter net revenue of $2.2 million, up from $2.1 million in the first quarter and $179,000 in the same quarter of 2013, the company announced in a news release.“We achieved an important milestone during the second quarter ... [Published Orthopedics Today - Aug 08 2014]
First reported Aug 05 2014 - Updated Aug 06 2014 - 2 reports

Alimera Sciences: Danish Health and Medicines Authority Grants Marketing Authorization to Iluvien

Alimera Sciences reported that the Danish Health and Medicines Authority has granted marketing authorization to Iluvien for the treatment of vision impairment associated with chronic diabetic macular edema considered insufficiently responsive to available ... [Published Individual.com - Aug 06 2014]
First reported Aug 02 2014 - Updated Aug 02 2014 - 1 reports

Denmark grants marketing authorisation to Alimera Sciences' Iluvien to treat chronic DME

The Danish Health and Medicines Authority has granted marketing authorisation to Alimera Sciences' Iluvien for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available t ... [Published PharmaBiz - Aug 02 2014]
First reported Jul 31 2014 - Updated Aug 01 2014 - 8 reports

Iluvien receives marketing approval in Denmark for chronic DME

The Danish Health and Medicines Authority has granted marketing approval of Iluvien for the treatment of vision impairment associated with chronic diabetic macular edema, according to an Alimera press release.Denmark is the second country to grant national ... [Published Orthopedics Today - Aug 01 2014]
First reported Jul 30 2014 - Updated Jul 31 2014 - 3 reports

pSivida: ILUVIEN Secures Marketing Authorization in Norway and Approval for Reimbursement in Portugal

pSivida reported that ILUVIEN has been has granted marketing authorization in Norway for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies and has been approved ... [Published Individual.com - Jul 31 2014]
First reported Jul 28 2014 - Updated Jul 29 2014 - 5 reports

pSivida Corp Announces Iluvien® Receives Marketing Authorization In Norway And Approval For Reimbursement In Portugal

WATERTOWN, MA – pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that ILUVIEN® has been has granted marketing authorization in Norway for the treatment ... [Published BioSpace - Jul 29 2014]

Quotes

...Net revenue for the six months ended June 30, 2014 was $4.27 million, compared to $179,000 for the same period ended June 30, 2013. "We achieved an important milestone during the second quarter of 2014 as more commercial patients have now been injected with ILUVIEN than were treated in our clinical trials. Further, we experienced a 25% increase in ILUVIEN injections in the UK during the second quarter of 2014 compared to the prior quarter. Our second quarter 2014 revenue from the UK was similar to the first quarter revenue as several hospitals in the UK stocked their pharmacies following the implementation of the NICE guidance for the reimbursement of ILUVIEN in the first quarter 2014" said Dan Myers, president and CEO of Alimera Sciences
"As our operations continue to expand, we expect to experience fluctuations in order patterns but we believe the underlying organic growth rate of Iluvien injections in the United Kingdom is a strong sign of the demand we are seeing. We expect usage to continue to increase as the United Kingdom market becomes more familiar with the available treatments for diabetic macular edema."
Original Article: NEXT ARTICLE More From BioPortfolio on "pSivida Corp.: Imminent New Drug Approval, Steady News Flow, And Tethadur Partnership Raising Price Target To $10/Share"
Citi's ophthalmology expert noted that he believes that "the usage of Avastin will increase dramatically at the Cleveland Clinic from current levels of 40-50% to 80% over time as the institution moves towards a capitated, episodic care model under the Affordable Care Act. This new model will also reduce usage of both Eylea and Lucentis as they are expensive and offer little benefit over Avastin. The expert generally uses Eylea and Lucentis in most of his patients who have good insurance and Avastin is used in the rest of patients. But that is not the mainstream at the Clinic where Avastin is oftentimes used ahead of the branded drugs. The Clinic has its own Avastin compounding lab and so they are not worried about the risk of infections."

More Content

All (71) | News (37) | Reports (0) | Blogs (34) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Your September Biotech Back-to-School Calendar [Published TheStreet.com - 19 hours ago]
Alimera Sciences reports net income for Q2 [Published Individual.com - Aug 22 2014]
3 smart-money growth stocks to boost your returns [Published Motley Fool - Aug 21 2014]
2nd Half Of 2014 Biotechnology Catalysts--Part 4 [Published Seeking Alpha - Aug 18 2014]
ALIMERA SCIENCES : Reports 2Q Financial Results [Published 4 Traders - Aug 16 2014]
Biotech Stock Directory Update [Published InvestorIdeas.com - Aug 14 2014]
pSivida Corp.: Imminent New Drug Approval, Stea... [Published BioPortfolio - Aug 12 2014]
pSivida Corp.: Imminent New Drug Approval, Stea... [Published Seeking Alpha - Aug 12 2014]
Alimera Sciences Issues 2Q Financial Results [Published Individual.com - Aug 12 2014]
Alimera receives marketing authorization for DM... [Published Individual.com - Aug 11 2014]
Alimera Sciences' (ALIM) CEO Charles Myers on Q... [Published Seeking Alpha - Aug 10 2014]
Alimera reports net revenue of $2.2 million in ... [Published Orthopedics Today - Aug 08 2014]
What You Missed From Regulatory Agencies Last W... [Published Pharmaceutical Online - Aug 08 2014]
Alimera Sciences Reports Second Quarter 2014 Fi... [Published Bio-Medicine - Aug 07 2014]
Alimera Sciences Reports Second Quarter 2014 Fi... [Published Wall Street Select - Aug 07 2014]
New Research Looking at Managing Insufficiently... [Published Wall Street Select - Aug 06 2014]
Alimera Sciences: Danish Health and Medicines A... [Published Individual.com - Aug 06 2014]
Alimera receives marketing authorization for vi... [Published Individual.com - Aug 05 2014]
Denmark grants marketing authorisation to Alime... [Published PharmaBiz - Aug 02 2014]
Iluvien receives marketing approval in Denmark ... [Published Orthopedics Today - Aug 01 2014]
pSivida Corp Reports ILUVIEN® For Chronic Diabe... [Published BioSpace - Aug 01 2014]
pSivida announces expansion of marketing author... [Published Individual.com - Aug 01 2014]
Alimera' ILUVIEN gets marketing authorization i... [Published PBR - News - Aug 01 2014]
Alimera: Iluvien Marketing Authorization In Den... [Published RTTNews.com - Jul 31 2014]
pSivida Corp. Reports ILUVIEN for Chronic Diabe... [Published FinanzNachrichten.de - Jul 31 2014]
pSivida Corp. Reports ILUVIEN® for Chronic Diab... [Published Business Wire Health News - Jul 31 2014]
Alimera Sciences' ILUVIEN® Receives Marketing A... [Published PR Newswire: General Business - Jul 31 2014]
pSivida: ILUVIEN Secures Marketing Authorizatio... [Published Individual.com - Jul 31 2014]
Norwegian Medicines Evaluation Board Grants Mar... [Published Individual.com - Jul 31 2014]
Iluvien approved in Norway: pSivida [Published Australian Life Scientist - Jul 30 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Alimera' ILUVIEN gets marketing authorization i... [Published PBR - News - Aug 01 2014]
US-based biopharmaceutical firm Alimera Sciences has received marketing authorization from the Danish Health and Medicines Authority for ILUVIEN to treat vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently ...
pSivida Corp. Reports ILUVIEN® for Chronic Diab... [Published Business Wire Health News - Jul 31 2014]
WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida reports Iluvien for Chronic DME receives Marketing Authorization in Denmark, 9th EU approval ...
Alimera Sciences' ILUVIEN® Receives Marketing A... [Published PR Newswire: General Business - Jul 31 2014]
ATLANTA, July 31, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the ...
Alimera' ILUVIEN gets marketing authorization i... [Published PBR - News - Jul 29 2014]
US-based biopharmaceutical firm Alimera Sciences has received marketing authorization from the Norwegian Medicines Evaluation Board for ILUVIEN to treat vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive ...
pSivida Announces ILUVIEN® Receives Marketing A... [Published Business Wire Health News - Jul 28 2014]
WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida announces ILUVIEN receives marketing authorization in Norway and approval for reimbursement in Portugal ...
1 2 3 4 5 6 7
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.